Novartis has proposed to acquire French contract development and manufacturing organizations (French CDMO) CellforCure from LFB for an undisclosed price. CellforCure is engaged in producing cell and gene therapies across Europe. The deal proposed by Novartis includes the cell and gene manufacturing facility in Les Ulis near Paris and the related adjacent land. If the […]
Continue reading …
Novartis breast cancer drug Kisqali (ribociclib) plus endocrine therapy has succeeded in extending progression-free survival (PFS) compared to only endocrine therapy in three phase 3 MONALEESA trials. The findings come from the Swiss pharma company’s release of data from subgroup analyses of the three pivotal trials in pre-, peri- and postmenopausal women, irrespective of the […]
Continue reading …Novartis bags Gilenya EC approval for multiple sclerosis in young patients
December 2, 2018 No Comment
Gilenya EC approval : The European Commission (EC) has expanded the approval of Novartis multiple sclerosis drug Gilenya (fingolimod) to include the treatment of both children and adolescents, in the age group 10-17 years. Expanded Gilenya EC approval The expanded Gilenya EC approval is for the treatment of relapsing-remitting forms of multiple sclerosis (RRMS). Novartis already […]
Continue reading …Spark Therapeutics bags Luxturna EU approval for inherited retinal disease
November 24, 2018 No Comment
Luxturna EU approval for inherited retinal disease : Pennsylvania-based Spark Therapeutics has bagged the European Commission’s (EC) approval for its gene therapy Luxturna (voretigene neparvovec) to treat a rare inherited type of vision loss in both children and adults. Luxturna EU approval for inherited retinal disease Luxturna, an adeno-associated viral (AAV) vector gene therapy has […]
Continue reading …Novartis’ Promacta bags FDA approval for first-line severe aplastic anemia
November 19, 2018 No Comment
Promacta FDA approval : The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’ Promacta (eltrombopag) to cover the treatment of severe aplastic anemia (SAA) in the first-line setting in combination with standard immunosuppressive therapy (IST). New Promacta FDA approval for first-line severe aplastic anemia The new Promacta FDA approval is […]
Continue reading …
The European Commission (EC) has approved a label update for Novartis psoriatic arthritis drug Cosentyx (secukinumab) to include dosing flexibility for treating the condition. Cosentyx is the first and only fully-human treatment that precisely prevents interleukin-17A (IL-17A), in psoriatic arthritis, which is a chronic, progressive and irreversible disease that causes pain, fatigue, and also activity […]
Continue reading …
Swiss pharma giant Novartis has signed a deal valued at about $2.1 billion to acquire US biopharma company Endocyte in a move to expand its expertise in radiopharmaceuticals for the treatment of cancer. According to the merger terms, the Swiss pharma giant will buy all the shares of Endocyte at $24 per share. The US […]
Continue reading …
Pharma acquisition news : Sandoz US, a subsidiary of Swiss pharma company Novartis, has agreed to sell its dermatology and oral solids businesses to Indian pharma company Aurobindo Pharma in a deal that could fetch it up to $1 billion. As per the terms of the deal, the Indian pharma company through its subsidiary Aurobindo […]
Continue reading …US CDMO Avara acquires sterile manufacturing facility in Boucherville from Sandoz
September 8, 2018 No Comment
Avara Pharmaceutical Services, a US CDMO (contract development and manufacturing organization), has completed a previously announced acquisition of a Canadian sterile manufacturing facility for injectable medicines in Boucherville, Quebec, from Novartis’ Sandoz division. The financial terms of the acquisition of the injectables production facility were not disclosed. The deal, which marks the entry of the […]
Continue reading …
Novartis has secured approval from the European Commission (EC) for its skin cancer drug combo Tafinlar (dabrafenib) and Mekinist (trametinib) as an adjuvant therapy for stage III patients with BRAF V600 mutation-positive melanoma after complete surgical resection. The latest approval marks the third for the Tafinlar-Mekinist combination in Europe for various tumor types identified with […]
Continue reading …
Business News Today
- Relation Insurance Services acquires employee surety firm Pope & Young
- Arch Re set to take majority stake in Precision Marketing Asia Pacific
- Ascend Performance to acquire Poliblend and Esseti Plast GD from D’Ottavio
- Graco introduces Fusion ProConnect spray gun
- Gibraltar Industries buys assets of Delta Separations for $50m
- Domtar to acquire Appvion’s POS paper business
- Platinum Equity acquires sweet biscuits manufacturer Biscuit International
- TASI acquires German inspection systems manufacturer Cassel Messtechnik
- ALX Oncology raises $105m to advance clinical development of ALX148
- ImmunogenX enrolls patients for Solutions for Celiac trial of Latiglutenase
